Liftstream is an executive search recruitment company in the life sciences sector
Sanofi appoint Chief Patient Officer
Authored by James Sheppard
Posted in Executive Appointments, Pharmaceutical business, Recruitment Market
Tagged biotechnology, Chief Patient Officer, Dr Anne C. Beal, drug companies, engagement, Genzyme, Harvard Medical School, Pascale Witz, patient communities, patient groups, Patient-Centred Outcomes Research Institute, pharmaceutical, Rare Disease, Sanofi
Leave a comment
Osiris sells stem cell business in $100m deal
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged acute Graft vs Host Disease, aGvHD, Canada, Crohn's disease, europe, Genzyme, heart failure, Mesoblast, New Zealand, New Zealand Biotech, orthopaedics, Osiris, Prochymal, Sanofi, stem cell platform, Stem Cells, USA
Leave a comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
Pharma marries VCs to give birth to Biotechs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Amgen, Atlas Ventures, Avalon Ventures, biotech, Bruce Booth, celgene, collaborative business models, Francesco De Rubertis, Fund IX, GSK, Index Ventures, J&J, Johnson & Johnson, Kevin Johnson, Large Pharma, LSD, Nimbus Discovery, Novartis, Pangenetics, Paul Stoffels, pharma, Quanticel, R&D, Sanofi, Shire HGT, SR One, Third Rock Ventures, Tibotec, venture capital, Versant Ventures, Warp Drive Bio
Leave a comment
Sanofi Suffers Setback with two drugs
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged biPar Science, blockbuster, breast cancer, competitor, development program, ECLIPSE, Factor Xa inhibitor, failure, iniparib, Integrillin, Merck, non-small cell lung cancer, NSCLC, oncology, otamixaban, ovarian cancer, Sanofi, TAO results
Leave a comment
Ultragenyx focused on ultra-rare disease future
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged 2013, Baylor Research Institute, BioMarin, biotech, Emil Kakkis, Fatty Acid Oxidisation Disorders, funding, Genzyme, Heriditary Inclusion Body Myopathy, IPO, Liftstream, Rare Disease, rare disease day, Sanofi, Series B, Shire, Sialic Acid, Sly Syndrome, Sudden Infant Death Syndrome, triheptanoin, ultra-rare, Ultragenyx
Leave a comment
Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events:
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Actelion, Alexion, BioMarin, BlubirdBio, Chiesi, Elelyso, Emil Kakkis, Enobia, Forbes, Genzyme, IPO, Lysogene, M&A, Prosensa, Protalix, rare diseases, regulatory affairs, regulatory approval, Replagal, Sanofi, Shire, Soliris, Supernus Pharmaceuticals, ultra-rare diseases, Ultragenyx, uniQure, VPRIV
Leave a comment